000268721 001__ 268721
000268721 005__ 20250127091804.0
000268721 0247_ $$2pmc$$apmc:PMC11318394
000268721 0247_ $$2doi$$a10.1177/0271678X231221039
000268721 0247_ $$2ISSN$$a0271-678X
000268721 0247_ $$2ISSN$$a1559-7016
000268721 0247_ $$2altmetric$$aaltmetric:157703253
000268721 0247_ $$2pmid$$apmid:38087890
000268721 037__ $$aDZNE-2024-00300
000268721 041__ $$aEnglish
000268721 082__ $$a610
000268721 1001_ $$0P:(DE-2719)2811871$$aArboit, Alberto$$b0$$eFirst author
000268721 245__ $$aHemodynamic responses in the rat hippocampus are simultaneously controlled by at least two independently acting neurovascular coupling mechanisms
000268721 260__ $$aLondon$$bSage$$c2024
000268721 3367_ $$2DRIVER$$aarticle
000268721 3367_ $$2DataCite$$aOutput Types/Journal article
000268721 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1721819278_7924
000268721 3367_ $$2BibTeX$$aARTICLE
000268721 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000268721 3367_ $$00$$2EndNote$$aJournal Article
000268721 520__ $$a We combined electrical perforant pathway stimulation with electrophysiological and fMRI recordings in the hippocampus to investigate the effects of neuronal afterdischarges (nAD) on subsequent fMRI BOLD signals in the presence of isoflurane and medetomidine. These two drugs already alter basal hemodynamics in the hippocampus, with isoflurane being mildly vasodilatory and medetomidine being mildly vasoconstrictive. The perforant pathway was stimulated once for 8 seconds with either continuous 20 Hz pulses (continuous stimulation) or 8 bursts of 20 high-frequency pulses (burst stimulation). Burst stimulation in the presence of medetomidine elicited long-lasting nAD that coincided with a brief positive BOLD response and a subsequent long-lasting decrease in BOLD signals. Under isoflurane, this stimulation elicited only short-lasting nAD and only a short-lasting decline in BOLD signals. In contrast, continuous stimulation under isoflurane and medetomidine caused a similar duration of nAD. Under isoflurane, this caused only a sharp and prolonged decline in BOLD signals, whereas under medetomidine, again, only a brief positive BOLD response was elicited, followed by a shorter and moderate decline in BOLD signals. Our results suggest that nAD simultaneously activate different neurovascular coupling mechanisms that then independently alter local hemodynamics in the hippocampus, resulting in an even more complex neurovascular coupling mechanism.
000268721 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000268721 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000268721 650_2 $$2MeSH$$aAnimals
000268721 650_2 $$2MeSH$$aNeurovascular Coupling: physiology
000268721 650_2 $$2MeSH$$aNeurovascular Coupling: drug effects
000268721 650_2 $$2MeSH$$aIsoflurane: pharmacology
000268721 650_2 $$2MeSH$$aHippocampus: physiology
000268721 650_2 $$2MeSH$$aHippocampus: drug effects
000268721 650_2 $$2MeSH$$aHippocampus: blood supply
000268721 650_2 $$2MeSH$$aMedetomidine: pharmacology
000268721 650_2 $$2MeSH$$aMale
000268721 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000268721 650_2 $$2MeSH$$aRats
000268721 650_2 $$2MeSH$$aHemodynamics: drug effects
000268721 650_2 $$2MeSH$$aHemodynamics: physiology
000268721 650_2 $$2MeSH$$aElectric Stimulation
000268721 650_2 $$2MeSH$$aAnesthetics, Inhalation: pharmacology
000268721 650_2 $$2MeSH$$aRats, Wistar
000268721 650_2 $$2MeSH$$aPerforant Pathway: physiology
000268721 650_2 $$2MeSH$$aPerforant Pathway: drug effects
000268721 650_2 $$2MeSH$$aCerebrovascular Circulation: physiology
000268721 650_2 $$2MeSH$$aCerebrovascular Circulation: drug effects
000268721 650_7 $$2Other$$aBOLD-fMRI
000268721 650_7 $$2Other$$adentate gyrus
000268721 650_7 $$2Other$$ain vivo electrophysiology
000268721 650_7 $$2Other$$anegative BOLD response
000268721 650_7 $$2Other$$aneuronal afterdischarges
000268721 7001_ $$0P:(DE-2719)2278716$$aKrautwald, Karla$$b1
000268721 7001_ $$0P:(DE-2719)2810456$$aAngenstein, Frank$$b2$$eLast author
000268721 773__ $$0PERI:(DE-600)2039456-1$$a10.1177/0271678X231221039$$gp. 0271678X231221039$$n6$$p896 - 910$$tJournal of cerebral blood flow & metabolism$$v44$$x0271-678X$$y2024
000268721 8564_ $$uhttps://pub.dzne.de/record/268721/files/DZNE-2024-00300.pdf$$yOpenAccess
000268721 8564_ $$uhttps://pub.dzne.de/record/268721/files/DZNE-2024-00300.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000268721 909CO $$ooai:pub.dzne.de:268721$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000268721 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000268721 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000268721 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-08-19$$wger
000268721 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CEREBR BLOOD F MET : 2022$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-19
000268721 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CEREBR BLOOD F MET : 2022$$d2023-08-19
000268721 9141_ $$y2024
000268721 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811871$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000268721 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2278716$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000268721 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810456$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000268721 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000268721 9201_ $$0I:(DE-2719)1310004$$kAG Angenstein$$lFunctional Neuroimaging$$x0
000268721 980__ $$ajournal
000268721 980__ $$aVDB
000268721 980__ $$aI:(DE-2719)1310004
000268721 980__ $$aUNRESTRICTED
000268721 9801_ $$aFullTexts